Switch to Therapeutic Anticoagulation
In patients with paroxysmal atrial fibrillation, low-dose aspirin should be discontinued and therapeutic anticoagulation initiated based on stroke risk stratification, as aspirin is inferior to oral anticoagulation for stroke prevention regardless of AF pattern (paroxysmal, persistent, or permanent).
Risk Stratification Determines Treatment
The pattern of atrial fibrillation—whether paroxysmal, persistent, or permanent—does not change your approach to anticoagulation. Guidelines explicitly state that antithrombotic therapy should be selected using the same criteria irrespective of AF pattern 1, 2, 3.
For Patients with CHADS₂ Score ≥2 (High Risk)
- Oral anticoagulation is strongly recommended over aspirin 4
- Direct oral anticoagulants (DOACs) are preferred over warfarin 4, 5
- Aspirin provides inadequate stroke protection in this population 6
For Patients with CHADS₂ Score = 1 (Intermediate Risk)
- Oral anticoagulation is recommended over aspirin 4
- The benefit of stroke reduction outweighs bleeding risk in most patients
- Aspirin plus clopidogrel may be considered only if the patient refuses or cannot tolerate anticoagulation 4
For Patients with CHADS₂ Score = 0 (Low Risk)
- Consider using CHA₂DS₂-VASc for more comprehensive risk assessment 3
- If CHA₂DS₂-VASc ≥2: oral anticoagulation is reasonable 3
- If truly low risk (CHA₂DS₂-VASc 0-1): aspirin or no therapy may be acceptable 4
Evidence Supporting Anticoagulation Over Aspirin
The superiority of anticoagulation is well-established. A meta-analysis of 4,052 patients demonstrated that oral anticoagulation reduced ischemic stroke by 52% compared to aspirin (HR 0.48,95% CI 0.37-0.63), with this benefit extending specifically to paroxysmal AF patients (HR 0.32,95% CI 0.16-0.61) 6. Treating 1,000 patients for one year with anticoagulation instead of aspirin prevents 23 ischemic strokes while causing only 9 additional major bleeds 6.
Critical Pitfalls to Avoid
Do not continue aspirin simply because the AF is paroxysmal. Real-world data shows that 38-40% of AF patients at moderate-to-high stroke risk inappropriately receive aspirin alone 7, often because clinicians underestimate stroke risk in paroxysmal AF or overestimate bleeding risk with anticoagulation.
Do not combine aspirin with anticoagulation without a specific indication (such as recent acute coronary syndrome or stenting). The combination increases bleeding risk without reducing stroke or mortality 5. Recent evidence confirms that adding aspirin to DOACs in AF patients without atherosclerotic disease significantly increases major bleeding (RR 3.15) without reducing ischemic events 8.
Preferred Anticoagulation Regimen
When initiating anticoagulation:
- First-line: DOAC (apixaban 5 mg twice daily, rivaroxaban 20 mg daily, edoxaban 60 mg daily, or dabigatran 150 mg twice daily) 4, 5
- Adjust doses for renal function, age, and weight per drug-specific criteria 9
- Second-line: Warfarin (INR target 2.0-3.0) if DOACs are contraindicated or unavailable 1, 3
The most recent 2024 ESC guidelines reaffirm that antiplatelet drugs like aspirin are not an alternative to oral anticoagulation and should not be used for stroke prevention in AF, as they can lead to potential harm, especially in elderly patients 5.